• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key

image

Play button

image

Play button

image

Progress

1/18

Click to flip

18 Cards in this Set

  • Front
  • Back
Subclasses of IgG
IgG1
IgG2
IgG3
IgG4
Subclasses of IgA
IgA1
IgA2
Antibody avidity
Overall binding energy of all the binding sites with antigen
Half life of IgA
One week
What is the major antibody of milk and colostrum?
IgA
Function of IgD
Unknown
What is 75% of total circulating immunoglobulin?
IgG
Half life of IgG
3 weeks
IgG facilitates the elimination of microbes by
Opsonization
ADCC
Component activation
Neutralization of virus adn toxins
Opsonization
Phagocytosis triggered following binding of the Fc region of antibodies, bound by the pathogen, to FcγR on phagocytes
Neutralization
IgG binds antigen to inhibit the antigen's ability to bind to a cell surface receptor
Half life of IgG3
One week
What subtype of IgG is the most effective activator of complement?
IgG3
What antibody represents 15% of the total immunoglobulin?
IgM
Half life of IgM
5 - 7 days
Cross-linking
One antigen is bound by two antibodies
Cross-reactivity
Antibodies that have been generated to one epitope on an antigen can bind (usually with lower affinity) an epitope that is very similar on a different antigen
Limitations of monoclonal antibodies as therapeutic agents
HAMA response
Antibodies against mouse variable region domains in humanized chimeric antibodies
Size of antibody
Formation of immunoconjugates requires stable linkage to prevent deposition of free drug or radioisotope into healthy tissues
Treatment of cancers with immunoconjugates is limited by general lack of tissue specific antigens on most cancer cells